Collegium Pharmaceutical vs Corcept Therapeutics
Collegium Pharmaceutical reported revenue of $781 million in fiscal 2025, about the same as Corcept Therapeutics' $761 million in fiscal 2025. Collegium Pharmaceutical's revenue grew 23.6% in its latest year, and Corcept Therapeutics' grew 12.8%. Collegium Pharmaceutical had an operating margin of 23.0%, against 5.9% at Corcept Therapeutics. Free cash flow was $328 million at Collegium Pharmaceutical and $142 million at Corcept Therapeutics.
Side by side
| Collegium Pharmaceutical | Corcept Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $781M | $761M |
| Revenue growth | 23.6% | 12.8% |
| Revenue growth a year, last 5 years | 20.3% | 16.6% |
| Gross margin | 59.4% | 98.3% |
| Operating margin | 23.0% | 5.9% |
| Net margin | 8.1% | 13.1% |
| Free cash flow | $328M | $142M |
| Free cash flow margin | 42.0% | 18.6% |
| Return on capital | 53.4% | 15.7% |
| Net debt to EBITDA | −0.4x | −8.1x |
| Dividends and buybacks | $25M | $173M |
| Change in diluted share count | −1.8% | 5.7% |
| Last close | $23.21 | $87.12 |
| P/E at the last close | 18.7× | — |
| Insider trades, last 12 months | sold $7.2 million | bought $3.3 million, sold $96.1 million |
| Piotroski F-score | 6 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Collegium PharmaceuticalCorcept Therapeutics
Operating margin
Percent of revenue
Collegium PharmaceuticalCorcept Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Collegium PharmaceuticalCorcept Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Collegium Pharmaceutical and Corcept Therapeutics pages.